ABUS Stock Analysis: Buy, Sell, or Hold?
ABUS - Arbutus Biopharma Corporation Common Stock
$4.29
-0.16 (-3.60%)
▼
5d:
+1.18%
30d:
-8.72%
90d:
-11.09%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Distribution
ABUS is up 6.6% this week, but smart money is buying puts. Top strike: $4 2026-06-18 with 3,452 OI. Put ratio: 89% View Scanner →
Strength: 7.2/10
Get Alerted When ABUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABUS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ABUS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ABUS is currently trading at $4.29, which is considered slightly low relative to its 30-day fair value range of $4.26 to $4.65.
Technical Outlook: Technically, ABUS is showing sideways momentum. Immediate support is located at $4.14, while resistance sits at $4.64. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.63 (+31.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABUS is showing sideways momentum. Immediate support is located at $4.14, while resistance sits at $4.64. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.63 (+31.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.26 -
$4.65
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 31.3% below Wall St target ($5.63)
Fair Price Analysis
30-Day Fair Range
$4.26 -
$4.65
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.14
Resistance Level
$4.64
Current Trend
Sideways
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.25
Wall Street Target
$5.63
(+31.3%)
Revenue Growth (YoY)
-33.2%
Profit Margin
-237.9%
Share & Embed Analysis
Last updated: March 30, 2026 5:08 AM ET
Data refreshes hourly during market hours. Next update: 6:08 AM
Data refreshes hourly during market hours. Next update: 6:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 60 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 61 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
Advanced ABUS Option Strategies
Professional options setups generated by AI based on today's ABUS price and gamma walls.
